Status:

COMPLETED

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

Lead Sponsor:

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Conditions:

Dravet Syndrome

Lennox Gastaut Syndrome

Eligibility:

All Genders

2-18 years

Phase:

PHASE1

Brief Summary

This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol (CBD).

Eligibility Criteria

Inclusion

  • Key
  • Subject has a clinical diagnosis of DS or LGS, where convulsive seizures (generalized tonic clonic seizures, tonic seizures, atonic seizures, tonic/atonic seizures, focal seizures with clear observable motor signs) are not completely controlled by current AEDs.
  • All medications or interventions for epilepsy (including ketogenic diet \[KD\] and vagal nerve stimulation \[VNS\]) must be stable for at least 4 weeks prior to first ZX008 dose and are expected to remain stable throughout the study.
  • Subjects must be taking a stable dose of CBD for at least 4 weeks prior to first ZX008 dose.
  • Subject's source of CBD is expected to be consistent for at least 3 months during study participation.
  • Key

Exclusion

  • Subject has current or past history of cardiovascular or cerebrovascular disease, myocardial infarction or stroke.
  • Subject with current cardiac valvulopathy or pulmonary hypertension that the Investigator, parent/caregiver, Independent Cardiac Advisory Board, Independent Data and Safety Monitoring Committee, or sponsor deems clinically significant.
  • Subject has a current or past history of glaucoma.

Key Trial Info

Start Date :

January 19 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 24 2020

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT03467113

Start Date

January 19 2018

End Date

June 24 2020

Last Update

December 1 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

PANDA Neurology/CIRCA

Atlanta, Georgia, United States, 30328

2

MultiCare Institute for Research & Innovation

Tacoma, Washington, United States, 98405